European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 602-607 , December 2008

Relation between hemostatic parameters and prognostic/predictive factors in breast cancer

  • Engin Yigit

      Affiliations

    • Department of Internal Medicine, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey
    • ,
  • Güzin Gönüllü

      Affiliations

    • Department of Medical Oncology, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 362 3121919/3329; fax: +90 362 4576041.
    • ,
  • İdris Yücel

      Affiliations

    • Department of Medical Oncology, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey
    • ,
  • Mehmet Turgut

      Affiliations

    • Department of Hematology, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey
    • ,
  • Dilek Erdem

      Affiliations

    • Department of Internal Medicine, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey
    • ,
  • Burcu Çakar

      Affiliations

    • Department of Internal Medicine, Ondokuz Mayis University Medical School, Kurupelit/Samsun, Turkey

Received 12 April 2007 ,Revised 25 May 2007 ,Accepted 6 June 2007.

References 

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33
  2. Joensuu H, Toikanen S, Klemi PJ. DNA index and S-phase fraction and their combinations as prognostic factors in operable ductal breast carcinoma. Cancer. 1990;66:331–340
  3. Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol. 1992;10:686–695
  4. Mclntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995;11:885–891
  5. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001;37:347–354
  6. Marchetti P, Cannita K, Ricevuto E, et al. Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol. 2003;14:704–708
  7. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001;61:2505–2512
  8. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment?. J Natl Cancer Inst. 2003;95:1660–1673
  9. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001;3:371–384
  10. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost. 2004;30:5–20
  11. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3:99–114
  12. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999;91:22–36
  13. Iversen LH, Thorlacius-Ussing O. Systemic coagulation reactivation in recurrence of colorectal cancer. Thromb Haemost. 2003;89:726–734
  14. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27–34
  15. Glassman AB. Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci. 1997;27:391–395
  16. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P, Maragoudakis MM. Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol. 2000;19:345–351
  17. Loreto MF, De Martinis M, Corsi MP, Modesti M, Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res. 2000;6:301–312
  18. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:117–121
  19. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–3309
  20. Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis. 1988;18:37
  21. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metastasis. 1994;14:303
  22. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33:50–55
  23. van Duijnhoven EM, Lustermans FA, van Wersch JW. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis. 1993;23:168–172
  24. Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745–749
  25. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology. 2003;62:1078–1082
  26. Mielicki WP, Tenderenda M, Rutkowski P, Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett. 1999;146:61–66
  27. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis. 1993;4:249–254
  28. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–395
  29. Stockhaus C, Kohn B, Rudolph R, Brunnberg L, Giger U. Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. J Small Anim Pract. 1999;40:326–331
  30. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis. 1997;27:112–118
  31. Mannucci PM, Vaglini M, Maniezzo M, Magni E, Mari D, Cascinelli N. Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma. Eur J Cancer Clin Oncol. 1985;21:681–685
  32. Uzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer. A systematic review of the literature and meta-analysis. Cancer Research. 2004;64:2941–2955
  33. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8
  34. Facchini V, Gadducci A, Baicchi U, et al. Factor VIIIR: Ag plasma levels in patients with cervical and ovarian carcinoma. Eur J Oncol. 1988;9:87–93
  35. Gadducci A, Baicchi U, Marrai R, et al. Pretreatment plasma level of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical–pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol. 1993;49:354–358
  36. Paczuski R, Bialkowska A, Kotschy M, Burduk D, Betlejewski S. von Willebrand factor in plasma of patients with advanced stages of larynx cancer. Thromb Res. 1999;95:197–200
  37. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest. 1991;87:229–236
  38. Rohsig LM, Damin DC, Stefani SD, Castro CG, Roisenberg I, Schwartsmann G. von Willebrand factor antigen levels in plasma of patients with malignant breast disease. Braz J Med Biol Res. 2001;34:1125–1129
  39. Abbasciano V, Tassinari D, Sartori S, et al. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev. 1995;19:331–336
  40. Wayman J, O'Hanlon D, Hayes N, Shaw I, Griffin SM. Fibrinogen levels correlate with stage of disease in patients with esophageal cancer. Br J Surg. 1997;84:185–188
  41. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low- molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;21:266–271
  42. Williams CK, Pineo GF, Gallus AS, McCulloch PB. The relevance of platelet and fibrinogen kinetics and coagulation studies to extent of disease and performance status in patients with adenocarcinoma. Med Pediatr Oncol. 1980;8:367–374
  43. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600–608
  44. Kim HK, Song KS, Lee KR, Kang YH, Lee YJ, Lee ES. Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis. 2004;15:9–13
  45. Rella C, Coviello M, Frenza ND, et al. Plasma D-dimer measurement as a marker of gynecological tumors: comparison with CA 125. Tumori. 1993;79:347–351
  46. Mitter CG, Zielinski CC. Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol. 1991;117:259–262
  47. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004;98:93–98
  48. Farrel DH, al-Mondhiry HA. Human fibroblast adhesion to fibrinogen. Biochemistry. 1997;36:1123–1128
  49. Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis. 1988;18:37
  50. Dixit A, Kannan M, Mahapatra M, Choudhry VP, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol. 2006;81:171–174
  51. de Wolf CJ, Cupers RM, Bertina RM, Vos HL. The constitutive expression of anticoagulant protein S is regulated through multiple binding sites for Sp1 and Sp3 transcription factors in the protein S gene promoter. J Biol Chem. Jun 30 2006;281:17635–17643

PII: S0953-6205(08)00078-2

doi: 10.1016/j.ejim.2007.06.036

European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 602-607 , December 2008

Article Tools